Loading…
Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry
Background Using data from the GARFIELD - AF (Global Anticoagulant Registry in the FIELD -Atrial Fibrillation), we evaluated the impact of chronic kidney disease ( CKD ) stage on clinical outcomes in patients with newly diagnosed atrial fibrillation ( AF ). Methods and Results GARFIELD - AF is a pro...
Saved in:
Published in: | Journal of the American Heart Association 2019-02, Vol.8 (3), p.e010510 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c505t-dace1bf21fcfa1e795e6ad27ffcdfa99cce508c435e780b786adc27db00c35643 |
---|---|
cites | cdi_FETCH-LOGICAL-c505t-dace1bf21fcfa1e795e6ad27ffcdfa99cce508c435e780b786adc27db00c35643 |
container_end_page | |
container_issue | 3 |
container_start_page | e010510 |
container_title | Journal of the American Heart Association |
container_volume | 8 |
creator | Goto, Shinya Angchaisuksiri, Pantep Bassand, Jean-Pierre Camm, A John Dominguez, Helena Illingworth, Laura Gibbs, Harry Goldhaber, Samuel Z Goto, Shinichi Jing, Zhi-Cheng Haas, Sylvia Kayani, Gloria Koretsune, Yukihiro Lim, Toon Wei Oh, Seil Sawhney, Jitendra P S Turpie, Alexander G G van Eickels, Martin Verheugt, Freek W A Kakkar, Ajay K |
description | Background Using data from the GARFIELD - AF (Global Anticoagulant Registry in the FIELD -Atrial Fibrillation), we evaluated the impact of chronic kidney disease ( CKD ) stage on clinical outcomes in patients with newly diagnosed atrial fibrillation ( AF ). Methods and Results GARFIELD - AF is a prospective registry of patients from 35 countries, including patients from Asia (China, India, Japan, Singapore, South Korea, and Thailand). Consecutive patients enrolled (2013-2016) were classified with no, mild, or moderate-to-severe CKD , based on the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative guidelines. Data on CKD status and outcomes were available for 33 024 of 34 854 patients (including 9491 patients from Asia); 10.9% (n=3613) had moderate-to-severe CKD , 16.9% (n=5595) mild CKD , and 72.1% (n=23 816) no CKD . The use of oral anticoagulants was influenced by stroke risk (ie, post hoc assessment of CHA
DS
- VAS c score), but not by CKD stage. The quality of anticoagulant control with vitamin K antagonists did not differ with CKD stage. After adjusting for baseline characteristics and antithrombotic use, both mild and moderate-to-severe CKD were independent risk factors for all-cause mortality. Moderate-to-severe CKD was independently associated with a higher risk of stroke/systemic embolism, major bleeding, new-onset acute coronary syndrome, and new or worsening heart failure. The impact of moderate-to-severe CKD on mortality was significantly greater in patients from Asia than the rest of the world ( P=0.001). Conclusions In GARFIELD - AF , moderate-to-severe CKD was independently associated with stroke/systemic embolism, major bleeding, and mortality. The effect of moderate-to-severe CKD on mortality was even greater in patients from Asia than the rest of the world. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 01090362. |
doi_str_mv | 10.1161/JAHA.118.010510 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_d158a0604f88404a9bba98c1831727c3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_d158a0604f88404a9bba98c1831727c3</doaj_id><sourcerecordid>2179507733</sourcerecordid><originalsourceid>FETCH-LOGICAL-c505t-dace1bf21fcfa1e795e6ad27ffcdfa99cce508c435e780b786adc27db00c35643</originalsourceid><addsrcrecordid>eNpVksFu1DAQhiMEolXpmRvykUtaO4ljhwNStG3ahYVWFQhxsibOZNdVEm9tb9E-Dy-Kt1uq1hePZv75xh79SfKe0RPGSnb6pb6sYyRPKKOc0VfJYUYLkVaVpK-fxQfJsfe3NJ4yEzmv3iYHORVMlKw8TP5-gwmWOOIUCEwdYelvBEeuNkHbET2xPbmGYGLZk18mrMh3_DNsyZmB5WQ9dqQOzsBAGtM6MwxRaqcH0Gzl7GQ0-Wq6CXcNHsHjJ3KDfjNEWOPsSMIKybWzfo06mHskF_VNMz9fnJGU1E2ULo0PbvsuedPD4PH48T5KfjbnP2aX6eLqYj6rF6nmlIe0A42s7TPW6x4YiopjCV0m-l53PVSV1sip1EXOUUjaChmrOhNdS6nOeVnkR8l8z-0s3Kq1MyO4rbJg1EPCuqUCF4weUHWMS6AlLXopC1pA1bZQSc1kzkQmdB5Zn_es9aYdsdNxgQ6GF9CXlcms1NLeq7KgnFdlBHx8BDh7t0Ef1Gi8xrjiCe3Gq4zFD1Ih8t2s071Ux1V6h_3TGEbVzilq55QYSbV3Suz48Px1T_r_vsj_AeH8uvM</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2179507733</pqid></control><display><type>article</type><title>Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry</title><source>PubMed Central(OpenAccess)</source><source>Wiley Open Access</source><creator>Goto, Shinya ; Angchaisuksiri, Pantep ; Bassand, Jean-Pierre ; Camm, A John ; Dominguez, Helena ; Illingworth, Laura ; Gibbs, Harry ; Goldhaber, Samuel Z ; Goto, Shinichi ; Jing, Zhi-Cheng ; Haas, Sylvia ; Kayani, Gloria ; Koretsune, Yukihiro ; Lim, Toon Wei ; Oh, Seil ; Sawhney, Jitendra P S ; Turpie, Alexander G G ; van Eickels, Martin ; Verheugt, Freek W A ; Kakkar, Ajay K</creator><creatorcontrib>Goto, Shinya ; Angchaisuksiri, Pantep ; Bassand, Jean-Pierre ; Camm, A John ; Dominguez, Helena ; Illingworth, Laura ; Gibbs, Harry ; Goldhaber, Samuel Z ; Goto, Shinichi ; Jing, Zhi-Cheng ; Haas, Sylvia ; Kayani, Gloria ; Koretsune, Yukihiro ; Lim, Toon Wei ; Oh, Seil ; Sawhney, Jitendra P S ; Turpie, Alexander G G ; van Eickels, Martin ; Verheugt, Freek W A ; Kakkar, Ajay K ; GARFIELD‐AF Investigators</creatorcontrib><description>Background Using data from the GARFIELD - AF (Global Anticoagulant Registry in the FIELD -Atrial Fibrillation), we evaluated the impact of chronic kidney disease ( CKD ) stage on clinical outcomes in patients with newly diagnosed atrial fibrillation ( AF ). Methods and Results GARFIELD - AF is a prospective registry of patients from 35 countries, including patients from Asia (China, India, Japan, Singapore, South Korea, and Thailand). Consecutive patients enrolled (2013-2016) were classified with no, mild, or moderate-to-severe CKD , based on the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative guidelines. Data on CKD status and outcomes were available for 33 024 of 34 854 patients (including 9491 patients from Asia); 10.9% (n=3613) had moderate-to-severe CKD , 16.9% (n=5595) mild CKD , and 72.1% (n=23 816) no CKD . The use of oral anticoagulants was influenced by stroke risk (ie, post hoc assessment of CHA
DS
- VAS c score), but not by CKD stage. The quality of anticoagulant control with vitamin K antagonists did not differ with CKD stage. After adjusting for baseline characteristics and antithrombotic use, both mild and moderate-to-severe CKD were independent risk factors for all-cause mortality. Moderate-to-severe CKD was independently associated with a higher risk of stroke/systemic embolism, major bleeding, new-onset acute coronary syndrome, and new or worsening heart failure. The impact of moderate-to-severe CKD on mortality was significantly greater in patients from Asia than the rest of the world ( P=0.001). Conclusions In GARFIELD - AF , moderate-to-severe CKD was independently associated with stroke/systemic embolism, major bleeding, and mortality. The effect of moderate-to-severe CKD on mortality was even greater in patients from Asia than the rest of the world. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 01090362.</description><identifier>ISSN: 2047-9980</identifier><identifier>EISSN: 2047-9980</identifier><identifier>DOI: 10.1161/JAHA.118.010510</identifier><identifier>PMID: 30717616</identifier><language>eng</language><publisher>England: John Wiley and Sons Inc</publisher><subject>Administration, Oral ; Aged ; Aged, 80 and over ; Anticoagulants - administration & dosage ; Asia - epidemiology ; atrial fibrillation ; Atrial Fibrillation - complications ; Atrial Fibrillation - drug therapy ; Atrial Fibrillation - mortality ; chronic kidney disease ; Female ; Follow-Up Studies ; GARFIELD‐AF registry ; Humans ; Incidence ; Male ; Middle Aged ; Original Research ; outcomes research ; Prognosis ; Prospective Studies ; Registries ; registry ; Renal Insufficiency, Chronic - complications ; Renal Insufficiency, Chronic - mortality ; Renal Insufficiency, Chronic - therapy ; Risk Assessment - methods ; Risk Factors ; Severity of Illness Index ; Stroke - epidemiology ; Stroke - etiology ; Stroke - prevention & control ; Survival Rate - trends ; Time Factors</subject><ispartof>Journal of the American Heart Association, 2019-02, Vol.8 (3), p.e010510</ispartof><rights>2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c505t-dace1bf21fcfa1e795e6ad27ffcdfa99cce508c435e780b786adc27db00c35643</citedby><cites>FETCH-LOGICAL-c505t-dace1bf21fcfa1e795e6ad27ffcdfa99cce508c435e780b786adc27db00c35643</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405596/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405596/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30717616$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goto, Shinya</creatorcontrib><creatorcontrib>Angchaisuksiri, Pantep</creatorcontrib><creatorcontrib>Bassand, Jean-Pierre</creatorcontrib><creatorcontrib>Camm, A John</creatorcontrib><creatorcontrib>Dominguez, Helena</creatorcontrib><creatorcontrib>Illingworth, Laura</creatorcontrib><creatorcontrib>Gibbs, Harry</creatorcontrib><creatorcontrib>Goldhaber, Samuel Z</creatorcontrib><creatorcontrib>Goto, Shinichi</creatorcontrib><creatorcontrib>Jing, Zhi-Cheng</creatorcontrib><creatorcontrib>Haas, Sylvia</creatorcontrib><creatorcontrib>Kayani, Gloria</creatorcontrib><creatorcontrib>Koretsune, Yukihiro</creatorcontrib><creatorcontrib>Lim, Toon Wei</creatorcontrib><creatorcontrib>Oh, Seil</creatorcontrib><creatorcontrib>Sawhney, Jitendra P S</creatorcontrib><creatorcontrib>Turpie, Alexander G G</creatorcontrib><creatorcontrib>van Eickels, Martin</creatorcontrib><creatorcontrib>Verheugt, Freek W A</creatorcontrib><creatorcontrib>Kakkar, Ajay K</creatorcontrib><creatorcontrib>GARFIELD‐AF Investigators</creatorcontrib><title>Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry</title><title>Journal of the American Heart Association</title><addtitle>J Am Heart Assoc</addtitle><description>Background Using data from the GARFIELD - AF (Global Anticoagulant Registry in the FIELD -Atrial Fibrillation), we evaluated the impact of chronic kidney disease ( CKD ) stage on clinical outcomes in patients with newly diagnosed atrial fibrillation ( AF ). Methods and Results GARFIELD - AF is a prospective registry of patients from 35 countries, including patients from Asia (China, India, Japan, Singapore, South Korea, and Thailand). Consecutive patients enrolled (2013-2016) were classified with no, mild, or moderate-to-severe CKD , based on the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative guidelines. Data on CKD status and outcomes were available for 33 024 of 34 854 patients (including 9491 patients from Asia); 10.9% (n=3613) had moderate-to-severe CKD , 16.9% (n=5595) mild CKD , and 72.1% (n=23 816) no CKD . The use of oral anticoagulants was influenced by stroke risk (ie, post hoc assessment of CHA
DS
- VAS c score), but not by CKD stage. The quality of anticoagulant control with vitamin K antagonists did not differ with CKD stage. After adjusting for baseline characteristics and antithrombotic use, both mild and moderate-to-severe CKD were independent risk factors for all-cause mortality. Moderate-to-severe CKD was independently associated with a higher risk of stroke/systemic embolism, major bleeding, new-onset acute coronary syndrome, and new or worsening heart failure. The impact of moderate-to-severe CKD on mortality was significantly greater in patients from Asia than the rest of the world ( P=0.001). Conclusions In GARFIELD - AF , moderate-to-severe CKD was independently associated with stroke/systemic embolism, major bleeding, and mortality. The effect of moderate-to-severe CKD on mortality was even greater in patients from Asia than the rest of the world. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 01090362.</description><subject>Administration, Oral</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anticoagulants - administration & dosage</subject><subject>Asia - epidemiology</subject><subject>atrial fibrillation</subject><subject>Atrial Fibrillation - complications</subject><subject>Atrial Fibrillation - drug therapy</subject><subject>Atrial Fibrillation - mortality</subject><subject>chronic kidney disease</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>GARFIELD‐AF registry</subject><subject>Humans</subject><subject>Incidence</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Original Research</subject><subject>outcomes research</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Registries</subject><subject>registry</subject><subject>Renal Insufficiency, Chronic - complications</subject><subject>Renal Insufficiency, Chronic - mortality</subject><subject>Renal Insufficiency, Chronic - therapy</subject><subject>Risk Assessment - methods</subject><subject>Risk Factors</subject><subject>Severity of Illness Index</subject><subject>Stroke - epidemiology</subject><subject>Stroke - etiology</subject><subject>Stroke - prevention & control</subject><subject>Survival Rate - trends</subject><subject>Time Factors</subject><issn>2047-9980</issn><issn>2047-9980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVksFu1DAQhiMEolXpmRvykUtaO4ljhwNStG3ahYVWFQhxsibOZNdVEm9tb9E-Dy-Kt1uq1hePZv75xh79SfKe0RPGSnb6pb6sYyRPKKOc0VfJYUYLkVaVpK-fxQfJsfe3NJ4yEzmv3iYHORVMlKw8TP5-gwmWOOIUCEwdYelvBEeuNkHbET2xPbmGYGLZk18mrMh3_DNsyZmB5WQ9dqQOzsBAGtM6MwxRaqcH0Gzl7GQ0-Wq6CXcNHsHjJ3KDfjNEWOPsSMIKybWzfo06mHskF_VNMz9fnJGU1E2ULo0PbvsuedPD4PH48T5KfjbnP2aX6eLqYj6rF6nmlIe0A42s7TPW6x4YiopjCV0m-l53PVSV1sip1EXOUUjaChmrOhNdS6nOeVnkR8l8z-0s3Kq1MyO4rbJg1EPCuqUCF4weUHWMS6AlLXopC1pA1bZQSc1kzkQmdB5Zn_es9aYdsdNxgQ6GF9CXlcms1NLeq7KgnFdlBHx8BDh7t0Ef1Gi8xrjiCe3Gq4zFD1Ih8t2s071Ux1V6h_3TGEbVzilq55QYSbV3Suz48Px1T_r_vsj_AeH8uvM</recordid><startdate>20190205</startdate><enddate>20190205</enddate><creator>Goto, Shinya</creator><creator>Angchaisuksiri, Pantep</creator><creator>Bassand, Jean-Pierre</creator><creator>Camm, A John</creator><creator>Dominguez, Helena</creator><creator>Illingworth, Laura</creator><creator>Gibbs, Harry</creator><creator>Goldhaber, Samuel Z</creator><creator>Goto, Shinichi</creator><creator>Jing, Zhi-Cheng</creator><creator>Haas, Sylvia</creator><creator>Kayani, Gloria</creator><creator>Koretsune, Yukihiro</creator><creator>Lim, Toon Wei</creator><creator>Oh, Seil</creator><creator>Sawhney, Jitendra P S</creator><creator>Turpie, Alexander G G</creator><creator>van Eickels, Martin</creator><creator>Verheugt, Freek W A</creator><creator>Kakkar, Ajay K</creator><general>John Wiley and Sons Inc</general><general>Wiley</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20190205</creationdate><title>Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry</title><author>Goto, Shinya ; Angchaisuksiri, Pantep ; Bassand, Jean-Pierre ; Camm, A John ; Dominguez, Helena ; Illingworth, Laura ; Gibbs, Harry ; Goldhaber, Samuel Z ; Goto, Shinichi ; Jing, Zhi-Cheng ; Haas, Sylvia ; Kayani, Gloria ; Koretsune, Yukihiro ; Lim, Toon Wei ; Oh, Seil ; Sawhney, Jitendra P S ; Turpie, Alexander G G ; van Eickels, Martin ; Verheugt, Freek W A ; Kakkar, Ajay K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c505t-dace1bf21fcfa1e795e6ad27ffcdfa99cce508c435e780b786adc27db00c35643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Administration, Oral</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anticoagulants - administration & dosage</topic><topic>Asia - epidemiology</topic><topic>atrial fibrillation</topic><topic>Atrial Fibrillation - complications</topic><topic>Atrial Fibrillation - drug therapy</topic><topic>Atrial Fibrillation - mortality</topic><topic>chronic kidney disease</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>GARFIELD‐AF registry</topic><topic>Humans</topic><topic>Incidence</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Original Research</topic><topic>outcomes research</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Registries</topic><topic>registry</topic><topic>Renal Insufficiency, Chronic - complications</topic><topic>Renal Insufficiency, Chronic - mortality</topic><topic>Renal Insufficiency, Chronic - therapy</topic><topic>Risk Assessment - methods</topic><topic>Risk Factors</topic><topic>Severity of Illness Index</topic><topic>Stroke - epidemiology</topic><topic>Stroke - etiology</topic><topic>Stroke - prevention & control</topic><topic>Survival Rate - trends</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goto, Shinya</creatorcontrib><creatorcontrib>Angchaisuksiri, Pantep</creatorcontrib><creatorcontrib>Bassand, Jean-Pierre</creatorcontrib><creatorcontrib>Camm, A John</creatorcontrib><creatorcontrib>Dominguez, Helena</creatorcontrib><creatorcontrib>Illingworth, Laura</creatorcontrib><creatorcontrib>Gibbs, Harry</creatorcontrib><creatorcontrib>Goldhaber, Samuel Z</creatorcontrib><creatorcontrib>Goto, Shinichi</creatorcontrib><creatorcontrib>Jing, Zhi-Cheng</creatorcontrib><creatorcontrib>Haas, Sylvia</creatorcontrib><creatorcontrib>Kayani, Gloria</creatorcontrib><creatorcontrib>Koretsune, Yukihiro</creatorcontrib><creatorcontrib>Lim, Toon Wei</creatorcontrib><creatorcontrib>Oh, Seil</creatorcontrib><creatorcontrib>Sawhney, Jitendra P S</creatorcontrib><creatorcontrib>Turpie, Alexander G G</creatorcontrib><creatorcontrib>van Eickels, Martin</creatorcontrib><creatorcontrib>Verheugt, Freek W A</creatorcontrib><creatorcontrib>Kakkar, Ajay K</creatorcontrib><creatorcontrib>GARFIELD‐AF Investigators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals(OpenAccess)</collection><jtitle>Journal of the American Heart Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goto, Shinya</au><au>Angchaisuksiri, Pantep</au><au>Bassand, Jean-Pierre</au><au>Camm, A John</au><au>Dominguez, Helena</au><au>Illingworth, Laura</au><au>Gibbs, Harry</au><au>Goldhaber, Samuel Z</au><au>Goto, Shinichi</au><au>Jing, Zhi-Cheng</au><au>Haas, Sylvia</au><au>Kayani, Gloria</au><au>Koretsune, Yukihiro</au><au>Lim, Toon Wei</au><au>Oh, Seil</au><au>Sawhney, Jitendra P S</au><au>Turpie, Alexander G G</au><au>van Eickels, Martin</au><au>Verheugt, Freek W A</au><au>Kakkar, Ajay K</au><aucorp>GARFIELD‐AF Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry</atitle><jtitle>Journal of the American Heart Association</jtitle><addtitle>J Am Heart Assoc</addtitle><date>2019-02-05</date><risdate>2019</risdate><volume>8</volume><issue>3</issue><spage>e010510</spage><pages>e010510-</pages><issn>2047-9980</issn><eissn>2047-9980</eissn><abstract>Background Using data from the GARFIELD - AF (Global Anticoagulant Registry in the FIELD -Atrial Fibrillation), we evaluated the impact of chronic kidney disease ( CKD ) stage on clinical outcomes in patients with newly diagnosed atrial fibrillation ( AF ). Methods and Results GARFIELD - AF is a prospective registry of patients from 35 countries, including patients from Asia (China, India, Japan, Singapore, South Korea, and Thailand). Consecutive patients enrolled (2013-2016) were classified with no, mild, or moderate-to-severe CKD , based on the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative guidelines. Data on CKD status and outcomes were available for 33 024 of 34 854 patients (including 9491 patients from Asia); 10.9% (n=3613) had moderate-to-severe CKD , 16.9% (n=5595) mild CKD , and 72.1% (n=23 816) no CKD . The use of oral anticoagulants was influenced by stroke risk (ie, post hoc assessment of CHA
DS
- VAS c score), but not by CKD stage. The quality of anticoagulant control with vitamin K antagonists did not differ with CKD stage. After adjusting for baseline characteristics and antithrombotic use, both mild and moderate-to-severe CKD were independent risk factors for all-cause mortality. Moderate-to-severe CKD was independently associated with a higher risk of stroke/systemic embolism, major bleeding, new-onset acute coronary syndrome, and new or worsening heart failure. The impact of moderate-to-severe CKD on mortality was significantly greater in patients from Asia than the rest of the world ( P=0.001). Conclusions In GARFIELD - AF , moderate-to-severe CKD was independently associated with stroke/systemic embolism, major bleeding, and mortality. The effect of moderate-to-severe CKD on mortality was even greater in patients from Asia than the rest of the world. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 01090362.</abstract><cop>England</cop><pub>John Wiley and Sons Inc</pub><pmid>30717616</pmid><doi>10.1161/JAHA.118.010510</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2047-9980 |
ispartof | Journal of the American Heart Association, 2019-02, Vol.8 (3), p.e010510 |
issn | 2047-9980 2047-9980 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_d158a0604f88404a9bba98c1831727c3 |
source | PubMed Central(OpenAccess); Wiley Open Access |
subjects | Administration, Oral Aged Aged, 80 and over Anticoagulants - administration & dosage Asia - epidemiology atrial fibrillation Atrial Fibrillation - complications Atrial Fibrillation - drug therapy Atrial Fibrillation - mortality chronic kidney disease Female Follow-Up Studies GARFIELD‐AF registry Humans Incidence Male Middle Aged Original Research outcomes research Prognosis Prospective Studies Registries registry Renal Insufficiency, Chronic - complications Renal Insufficiency, Chronic - mortality Renal Insufficiency, Chronic - therapy Risk Assessment - methods Risk Factors Severity of Illness Index Stroke - epidemiology Stroke - etiology Stroke - prevention & control Survival Rate - trends Time Factors |
title | Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T15%3A58%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20and%201-Year%20Outcomes%20of%20Patients%20With%20Newly%20Diagnosed%20Atrial%20Fibrillation%20and%20Chronic%20Kidney%20Disease:%20Results%20From%20the%20Prospective%20GARFIELD%20-%20AF%20Registry&rft.jtitle=Journal%20of%20the%20American%20Heart%20Association&rft.au=Goto,%20Shinya&rft.aucorp=GARFIELD%E2%80%90AF%20Investigators&rft.date=2019-02-05&rft.volume=8&rft.issue=3&rft.spage=e010510&rft.pages=e010510-&rft.issn=2047-9980&rft.eissn=2047-9980&rft_id=info:doi/10.1161/JAHA.118.010510&rft_dat=%3Cproquest_doaj_%3E2179507733%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c505t-dace1bf21fcfa1e795e6ad27ffcdfa99cce508c435e780b786adc27db00c35643%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2179507733&rft_id=info:pmid/30717616&rfr_iscdi=true |